1-4 of 4
Farhad Sedarati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy

Nicholas J. Short, MD, Farhad Sedarati, Dan Zhao, Olga Tsukurov, Sharon Friedlander, Douglas V. Faller
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-136968
Published: 2020
Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Clinical Trials & Observations
Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona
Journal: Blood
Blood (2018) 131 (13): 1415–1424.
https://doi.org/10.1182/blood-2017-09-805895
Published: 2018
Includes: Supplemental data
Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD
Journal: Blood
Blood (2016) 128 (22): 98.
https://doi.org/10.1182/blood.V128.22.98.98
Published: 2016
Journal Articles

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Ronan T Swords, MD PhD FRCPI, FRCPath, Michael R Savona, MD, Michael B Maris, MD, Harry P Erba, MD PhD, Jesus G. Berdeja, MD, James M. Foran, MD, Zhaowei Hua, PhD, Hélène M Faessel, PharmD, PhD, Ajeeta B Dash, PhD, Farhad Sedarati, PhD, Bruce J Dezube, MD, Bruno C Medeiros, MD
Journal: Blood
Blood (2014) 124 (21): 2313.
https://doi.org/10.1182/blood.V124.21.2313.2313
Published: 2014